Skip to main content

Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy?

Abstract

Background

To define the factors associated with increased risk of isolated locoregional failure that may justify postmastectomy radiotherapy in patients with T1/2 breast cancer and 1–3 positive lymph nodes.

Methods

Between 1990 and 2002, 248 patients who had pT1–2 breast cancer and 1–3 positive lymph nodes were treated with mastectomy without radiotherapy (age 32–84, median 54).

Results

Median follow-up time was 82 months (range 2–189 months). For all patients, the 8-year isolated locoregional failure-free rate was 95 %. In univariate analysis, hormone receptor status and administration of hormone therapy were statistically significant factors, and vascular invasion was the borderline significant factor for isolated locoregional failure-free rates (P = 0.0377, 0.0181, and 0.0555, respectively). The 8-year isolated locoregional failure-free rates were 98 % for patients with positive hormone receptor status and 90 % for patients with negative hormone receptor status, 97 % for patients who received hormone therapy and 89 % for patients who did not receive hormone therapy, 92 % for patients with vascular invasion and 97 % for patients without vascular invasion. In multivariate analysis for hormone receptor status and vascular invasion, the former was statistically significant (P = 0.0491) and the latter was borderline significant (P = 0.0664). When patients had both negative hormone receptor and positive vascular invasion status, the 8-year isolated locoregional failure-free rates decreased to 83 %.

Conclusions

With regard to patients who had pT1/2 breast cancer and 1–3 positive lymph nodes, isolated locoregional failure was not common in general; however, patients who had both negative hormone receptor status and vascular invasion were comparatively high-risk patients for isolated locoregional failure.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997;337:949–55.

    CAS  PubMed  Article  Google Scholar 

  2. Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen. Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8.

    CAS  PubMed  Article  Google Scholar 

  3. Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, Jackson SM, Wilson KS, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116–26.

    PubMed  Article  Google Scholar 

  4. Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol. 2000;18:1220–9.

    CAS  PubMed  Google Scholar 

  5. Overgaard M. Overview of randomized trials in high risk breast cancer patients treated with adjuvant systemic therapy with or without postmastectomy irradiation. Semin Radiat Oncol. 1999;9:292–9.

    CAS  PubMed  Article  Google Scholar 

  6. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087–106.

    Google Scholar 

  7. Recht A, Edge SB, Solin LJ, Robinson DS, Estabrook A, Fine RE, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–69.

    CAS  PubMed  Google Scholar 

  8. NCCN Clinical Practice Guidelines in Oncology. Version 1.2012. Breast Cancer. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 25 March 2012.

  9. Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E, et al. Selecting breast cancer patients with T1–T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005;61:1337–47.

    PubMed  Article  Google Scholar 

  10. Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, et al. Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010;17:2899–908.

    PubMed  Article  Google Scholar 

  11. Goldhirsch A, Glick JH, Gelber RD, Senn HJ. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst. 1998;90:1601–8.

    CAS  PubMed  Article  Google Scholar 

  12. Smith BD, Smith GL, Haffty BG. Postmastectomy radiation and mortality in women with T1–2 node-positive breast cancer. J Clin Oncol. 2005;23:1409–19.

    PubMed  Article  Google Scholar 

  13. Wu SG, He ZY, Li FY, Wang JJ, Guo J, Lin Q, et al. The clinical value of adjuvant radiotherapy in patients with early stage breast cancer with 1 to 3 positive lymph nodes after mastectomy. Chin J Cancer. 2010;29:668–76.

    PubMed  Article  Google Scholar 

  14. Yang PS, Chen CM, Liu MC, Jian JM, Horng CF, Liu MJ, et al. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys. 2010;77:516–22.

    PubMed  Article  Google Scholar 

  15. Truong PT, Berthelet E, Lee J, Kader HA, Olivotto IA. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer. 2005;103:2006–14.

    PubMed  Article  Google Scholar 

  16. Overgaard M, Nielsen HM, Overgaad J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radioter Oncol. 2007;82:247–53.

    Article  Google Scholar 

  17. Kyndi M, Overgaard M, Nielsen HM, Sørensen FB, Knudsen H, Overgaard J. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radioter Oncol. 2009;90:74–9.

    Article  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yasushi Hamamoto.

About this article

Cite this article

Hamamoto, Y., Ohsumi, S., Aogi, K. et al. Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy?. Breast Cancer 21, 177–182 (2014). https://doi.org/10.1007/s12282-012-0369-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-012-0369-7

Keywords

  • Breast cancer
  • T1–2N1
  • Mastectomy
  • Locoregional failure
  • Postmastectomy radiotherapy